Across TCGA pan-cancer cohorts, DMWD mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated DMWD data layer compared with 24 for mass-spec protein and 5 for mutation status.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher DMWD mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated DMWD expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.
GBM, LUAD, and LSCC are the cancer types where DMWD mass-spec protein most reproducibly stratifies survival.